Alglucosidase alfa
From Wikipedia the free encyclopedia
| Clinical data | |
|---|---|
| Trade names | Myozyme, Lumizyme, others |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous[1][2] |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C4758H7262N1274O1369S35[4] |
| Molar mass | 105338 g·mol−1[4] |
  (what is this?) (verify) | |
Alglucosidase alfa, sold under the brand name Myozyme among others, is an enzyme replacement therapy (ERT) orphan drug for treatment of Pompe disease (Glycogen storage disease type II), a rare lysosomal storage disorder (LSD).[5] Chemically, the drug is an analog of the enzyme that is deficient in patients affected by Pompe disease, alpha-glucosidase. It is the first drug available to treat this disease.[2]
It was approved for medical use in the United States in April 2006, as Myozyme[6] and in May 2010, as Lumizyme.[7]
Medical uses[edit]
Alglucosidase alfa is indicated for people with Pompe disease (GAA deficiency).[1]
In 2014 the U.S. Food and Drug Administration announced the approval of alglucosidase alfa for treatment of people with infantile-onset Pompe disease, including people who are less than eight years of age. In addition, the Risk Evaluation and Mitigation Strategy (REMS) is being eliminated.[8]
Side effects[edit]
Common observed adverse reactions to alglucosidase alfa treatment are pneumonia, respiratory complications, infections and fever. More serious reactions reported include heart and lung failure and allergic shock. Myozyme boxes carry warnings regarding the possibility of life-threatening allergic response.[2]
Economics[edit]
Some American health plans have refused to subsidize Myozyme for adults because it lacks approval for treatment in adults, as well as its high cost (US$ 300,000 per year for life).[9]
In 2015, Lumizyme was ranked the costliest drug per patient, with an average charge of US$630,159.[10]
References[edit]
- ^ a b c "Lumizyme- alglucosidase alfa injection, powder, for solution". DailyMed. 22 February 2020. Retrieved 14 August 2020.
- ^ a b c "FDA Approves First Treatment for Pompe Disease". FDA. 2006-04-28. Archived from the original on May 19, 2006. Retrieved 2008-07-07.
- ^ "Myozyme (alglucosidase alfa) Injectable for intravenous infusion Initial U.S. Approval: 2006". DailyMed. Retrieved 18 December 2022.
- ^ a b c American Medical Association (USAN). "Alglucosidase alfa". Statement on a Nonproprietary Name Adopted by the USAN Council. Archived from the original (Microsoft Word) on 12 February 2012. Retrieved 18 December 2007.
- ^ Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. (January 2007). "Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease". Neurology. 68 (2): 99–109. doi:10.1212/01.wnl.0000251268.41188.04. PMID 17151339.
- ^ "Drug Approval Package: Myozyme (Alglucosidase Alfa) NDA #125141". U.S. Food and Drug Administration. Retrieved 14 August 2020.
- ^ "Drug Approval Package: Lumizyme (alglucosidase alfa) NDA #125291". U.S. Food and Drug Administration. Retrieved 14 August 2020.
- Lay summary in: "Center for Drug Evaluation and Research: Application Number: 125291: Summary Review" (PDF). Food and Drug Administration.
- ^ "FDA expands approval of drug to treat Pompe disease to patients of all ages; removes risk mitigation strategy requirements". FDA. 2014-08-14. Archived from the original on 2014-08-03.
- ^ Anand G (2007-09-18). "As Costs Rise, New Medicines Face Pushback". The Wall Street Journal. Retrieved 2008-07-07.
- ^ "Magellan Rx Management Medical Pharmacy Trend Report" (PDF) (7th ed.). 2016. Archived from the original (PDF) on 29 March 2019.
External links[edit]
- "Alglucosidase Alfa". Drug Information Portal. U.S. National Library of Medicine.
